Pfizer Inc.
- Open
- 25.33
- Day high
- 25.65
- Day low
- 24.97
- Prev close
- 25.14
- Volume
- 38.8M
- Mkt cap
- $142.8B
- P/E (TTM)
- 19.1
- EPS (TTM)
- $1.31
- P/B
- 1.6
- P/S
- 2.3
- Yield
- 6.87%
- Per share
- $1.72
- ▼Insiders net selling -$51K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions mixed (13F)
Pfizer Inc. (PFE) is a Healthcare company listed on NYSE. The stock is up 2% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 7 published research articles covering PFE.
Pfizer Inc. (PFE) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 8 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PFE earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $0.72 | $0.75 | +3.9% | $14.5B | +4.4% |
| Feb 3, 2026 | $0.57 | $0.66 | +16.4% | $17.6B | +4.2% |
| Nov 4, 2025 | $0.63 | $0.87 | +37.4% | $16.7B | +0.9% |
| Apr 29, 2025 | $0.67 | $0.92 | +38.1% | $13.7B | -1.5% |
| Feb 4, 2025 | $0.47 | $0.63 | +33.6% | $17.8B | +2.4% |
| May 1, 2024 | $0.52 | $0.82 | +58.9% | $14.9B | +7.2% |
| Jan 30, 2024 | $-0.19 | $0.10 | +152.6% | $14.2B | +0.0% |
| Oct 31, 2023 | $-0.32 | $-0.17 | +46.9% | $13.2B | +4.0% |
| Aug 1, 2023 | $0.56 | $0.67 | +19.6% | $12.7B | +5.4% |
| May 2, 2023 | $0.98 | $1.23 | +25.5% | $18.3B | +10.2% |
| Jan 31, 2023 | $1.05 | $1.14 | +8.6% | $24.3B | -0.4% |
| Nov 1, 2022 | $1.39 | $1.78 | +28.1% | $22.6B | +7.4% |
PFE insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | BOURLA ALBERTdirector, officer: Chairman & CEO | Grant | 25 | — |
| Jun 30, 2026 | NARAYEN SHANTANUdirector | Grant | 2,058 | — |
| Jun 30, 2026 | SMITH JAMES Cdirector | Grant | 1,853 | — |
| Jun 30, 2026 | Buckley Mortimer Jdirector | Grant | 1,544 | — |
| Jun 30, 2026 | Taraporevala Cyrusdirector | Grant | 1,544 | — |
| Jun 30, 2026 | Quincey Jamesdirector | Grant | 1,595 | — |
| Jun 30, 2026 | Echevarria Josephdirector | Grant | 1,904 | — |
| Jun 16, 2026 | BOURLA ALBERTdirector, officer: Chairman & CEO | Grant | 23 | — |
| Jun 10, 2026 | DAMICO JENNIFER B.officer: SVP & Controller | Sell | 2,000 | $25.70 |
| Jun 1, 2026 | BOURLA ALBERTdirector, officer: Chairman & CEO | Grant | 23 | — |
| May 18, 2026 | BOURLA ALBERTdirector, officer: Chairman & CEO | Grant | 24 | — |
| May 4, 2026 | BOURLA ALBERTdirector, officer: Chairman & CEO | Grant | 22 | — |
| Apr 27, 2026 | SMITH JAMES Cdirector | Grant | 7,687 | — |
| Apr 27, 2026 | Desmond-Hellmann Susandirector | Grant | 7,687 | — |
| Apr 27, 2026 | Echevarria Josephdirector | Grant | 7,687 | — |
Source: PFE SEC Form 4 filings, latest Jul 1, 2026. For informational purposes only — not investment advice.
See the full PFE insider & 13F page →PFE research & analysis
LLY, MRK, PFE: 2026 Biotech M&A Patent Cliff Driver
Biotech M&A 2026 on track for best year since 2018. Patent cliffs (Keytruda 2028, Trulicity 2027) drive LLY/MRK/PFE acquisition urgency.
LLYMRKABBVLLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
LLYMRKBMYPharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
LLYAMGNABBVTrump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
MRKLLYTMOPharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
LLYAMGNABBVFTC Insulin Crackdown: CVS Settles — What It Means for LLY, NVO, and WBA
CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.
CVSWBALLYPharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
MRKLLYTMO
Pfizer Inc. company profile
Overview
Pfizer Inc. (NYSE:PFE) is one of the world's largest pharmaceutical companies, founded in 1849 in Brooklyn, New York by cousins Charles Pfizer and Charles Erhart. Originally starting as a fine chemicals business, the company evolved into a major pharmaceutical manufacturer and became publicly traded in 1972. Today, Pfizer is a global biopharmaceutical giant headquartered in New York, known for discovering, developing, manufacturing, and commercializing medicines and vaccines across multiple therapeutic areas. The company gained unprecedented prominence during the COVID-19 pandemic as the co-developer of the first FDA-authorized COVID-19 vaccine (Comirnaty) in partnership with BioNTech, and the oral COVID-19 treatment Paxlovid.
Business
Pfizer operates in the biopharmaceutical industry, which involves the research, development, manufacturing, and commercialization of drugs derived from biological sources or using biotechnology processes. The company's business spans multiple therapeutic areas and can be broadly categorized into several key segments: Oncology represents Pfizer's fastest-growing segment, significantly bolstered by the 2023 acquisition of Seagen, a leading antibody-drug conjugate (ADC) company. This segment includes cancer treatments such as Ibrance (breast cancer), Xtandi (prostate cancer), Padcev (bladder cancer), and Elrexfio (multiple myeloma). ADCs are sophisticated cancer treatments that combine targeted antibodies with potent chemotherapy drugs, allowing for precise delivery of toxic agents directly to cancer cells while minimizing damage to healthy tissue. Primary Care encompasses widely-used medications including Eliquis (blood thinner for stroke prevention), the Vyndaqel family (treatments for a rare heart condition called transthyretin amyloid cardiomyopathy), and Nurtec (migraine prevention and treatment). This segment typically generates steady, predictable revenues from established medications. Vaccines includes the Prevnar family (pneumococcal vaccines preventing pneumonia and meningitis), Comirnaty (COVID-19 vaccine developed with BioNTech), and Abrysvo (RSV vaccine for respiratory syncytial virus). Vaccines represent a high-margin business with significant global health impact. COVID-19 Products became a major revenue driver during the pandemic, including both the Comirnaty vaccine and Paxlovid oral treatment. While revenues from these products have declined from peak pandemic levels, they continue to provide substantial income as COVID-19 transitions to an endemic disease. Based on recent financial data, oncology and primary care each represent approximately 25-30% of non-COVID revenues, with vaccines comprising roughly 15-20%, and the remainder from specialty medicines and other therapeutic areas.
Revenue model
Pfizer generates revenue primarily through product sales of prescription medications and vaccines to a diverse customer base including wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and healthcare providers. The company operates a traditional pharmaceutical business model where it invests heavily in research and development, obtains regulatory approval for new drugs, and then commercializes these products during their patent protection period. The company's customers vary by product type and geography. For vaccines, major customers include government health agencies like the CDC and international health organizations. For prescription drugs, the primary customers are pharmaceutical wholesalers (such as McKesson, Cardinal Health, and AmerisourceBergen) who then distribute to pharmacies and healthcare facilities. Pfizer also sells directly to large hospital systems and specialty pharmacies for certain products. Revenue generation follows several patterns. Patent-protected products command premium pricing and generate the highest margins, particularly specialty medicines for rare diseases like Vyndaqel. Established products face generic competition after patent expiry, leading to significant revenue declines. Vaccines often have longer commercial lifecycles due to manufacturing complexity and regulatory barriers. Several factors influence Pfizer's margins and profitability. Positive margin drivers include successful new product launches, international expansion of existing products, price increases on established products, manufacturing efficiencies, and cost reduction programs. The company is currently executing a cost realignment program targeting $7.7 billion in cumulative savings by 2027. Negative margin pressures come from patent expirations leading to generic competition, pricing pressure from government health programs and insurance companies, increasing R&D costs for complex biologics and ADCs, manufacturing inflation, and regulatory requirements. The Inflation Reduction Act in the US allows Medicare to negotiate prices for certain high-cost drugs, though Pfizer currently has limited exposure with only one product selected for negotiation.
Competitive moat
Pfizer's competitive moat is moderately strong but faces ongoing challenges typical of large pharmaceutical companies. The company's primary moat stems from its intellectual property portfolio, with patents providing temporary monopolies on innovative drugs typically lasting 10-20 years from discovery. During this exclusivity period, Pfizer can command premium pricing, particularly for specialty medicines treating rare diseases or complex conditions. The company benefits from regulatory barriers that make competition difficult. Drug development requires extensive clinical trials, regulatory approval processes, and substantial capital investment, creating high barriers to entry. Manufacturing capabilities, particularly for complex biologics and vaccines, provide additional protection as these processes are difficult to replicate and require specialized facilities and expertise. Pfizer's scale advantages include a global commercial infrastructure, established relationships with healthcare providers and regulatory agencies, and the financial resources to fund large, expensive clinical trials. The recent Seagen acquisition strengthened its position in oncology, particularly in the rapidly growing ADC market where technical expertise creates competitive barriers. However, Pfizer's moat has notable vulnerabilities. Patent expirations inevitably lead to generic competition and dramatic revenue declines for individual products. The company faces intense pricing pressure from government health programs, insurance companies, and pharmacy benefit managers. Large competitors like Johnson & Johnson, Roche, and Novartis have similar capabilities and resources. Additionally, the rise of biosimilars (generic versions of biologic drugs) is creating new competitive pressures in previously protected markets. Disruption risks include breakthrough therapies from smaller biotech companies, gene and cell therapies that could provide one-time cures rather than chronic treatments, and potential changes in healthcare policy that could further restrict drug pricing. The company's dependence on a relatively small number of blockbuster drugs creates concentration risk when key patents expire.
Risks & safety
Pfizer presents a moderate margin of safety with solid financial fundamentals but some areas of concern. Liquidity and Solvency: 1. Cash position is relatively low at $1.4 billion with limited short-term investments 2. Current ratio of 1.26 indicates adequate short-term liquidity but not exceptional 3. Debt-to-equity ratio of 0.68 shows manageable leverage levels 4. Strong operating cash flow generation of $12.7 billion in 2024 provides financial flexibility 5. No immediate solvency concerns given large asset base and cash generation capability Valuation Metrics: 1. P/E ratio of 12.1 appears reasonable for a large pharmaceutical company 2. EV/EBITDA of 10.1 suggests fair valuation relative to earnings 3. Price-to-book ratio of 1.59 indicates modest premium to book value 4. Graham number analysis suggests potential undervaluation at current levels Other Considerations: 1. Revenue concentration risk from COVID-19 products, though declining 2. Patent cliff exposure requiring successful new product launches 3. Strong dividend history provides income support 4. Large R&D investment ($10.8 billion in 2024) maintains innovation pipeline
Recent development
Over the past few years, Pfizer has undergone significant strategic transformation focused on strengthening its core pharmaceutical business while managing the transition away from peak COVID-19 revenues. The most significant development was the $43 billion acquisition of Seagen completed in 2023, which immediately established Pfizer as a leader in antibody-drug conjugates (ADCs) and significantly enhanced its oncology capabilities. This acquisition brought promising pipeline assets and established commercial products like Padcev and Adcetris. The company has implemented a comprehensive cost realignment program targeting $7.7 billion in cumulative savings by 2027, focusing on manufacturing optimization, operational efficiency, and strategic use of digital tools and artificial intelligence. This program aims to maintain R&D investment levels while improving overall margins as COVID-19 revenues normalize. Pfizer has refined its commercial strategy by separating US and international operations and focusing resources on key growth products across four core therapeutic areas: oncology, vaccines, internal medicine, and inflammation & immunology. The company has strengthened its market positions in several areas, achieving leadership in pneumococcal vaccines with Prevnar20 and gaining significant market share in RSV prevention with Abrysvo. Pipeline advancement has been a major focus, with the company progressing multiple late-stage programs. In oncology, Pfizer is advancing several ADC candidates in Phase III trials and developing next-generation cancer treatments. The obesity pipeline represents a new growth opportunity, with oral GLP-1 and GIP antagonist candidates in development. Vaccine innovation continues with next-generation pneumococcal vaccines targeting 25+ serotypes and various other vaccine candidates. The company has also adapted its COVID-19 strategy, successfully transitioning these products to commercial markets while maintaining them as a sustainable revenue source correlated with infection rates rather than pandemic-driven government purchases.
PFE company profile · for informational purposes only — not investment advice.
Track PFE with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free